The chemical class identified as KCTD4 Activators comprises a diverse assortment of compounds that, through various indirect mechanisms, can influence the activity of KCTD4 (Potassium Channel Tetramerization Domain Containing 4). This category of chemicals is not unified by a shared chemical structure or a direct interaction with KCTD4. Instead, these compounds are characterized by their ability to modulate signaling pathways and cellular processes in which KCTD4 is implicated. KCTD4 is involved in the modulation of GABA receptors and the regulation of potassium channel functioning, playing a role in neurotransmitter systems and ion channel dynamics. The activators in this class exert their influence on these systems, thereby potentially affecting the functional role of KCTD4 within these contexts.
The KCTD4 Activators include molecules that act on GABAergic signaling, such as Picrotoxin and Bicuculline, known GABA receptor antagonists, which could indirectly influence KCTD4's regulatory role in these pathways. Similarly, compounds like Diazoxide and Quinidine, which affect potassium channels, may impact the pathways where KCTD4 is active. This class also encompasses compounds like Forskolin, which increases cAMP levels, potentially affecting GABA receptor regulation and other related pathways. Additionally, chemicals such as Ethanol and Caffeine, which modulate various neurotransmitter systems, could also indirectly impact KCTD4-related pathways. These activators, through their distinct mechanisms, highlight the complexity of cellular signaling and the intricate ways in which different biochemical pathways can intersect, leading to the modulation of specific proteins like KCTD4. The diversity in their action underscores the multifaceted nature of neurotransmitter regulation and ion channel dynamics, demonstrating how modulation of one aspect of these systems can ripple through to affect various components, including regulatory proteins like KCTD4.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Increases cAMP levels, potentially affecting GABA receptor regulation, where KCTD4 is involved. | ||||||
Diazoxide | 364-98-7 | sc-200980 | 1 g | $300.00 | 5 | |
Opens potassium channels, potentially influencing pathways where KCTD4 plays a role. | ||||||
Picrotoxin | 124-87-8 | sc-202765 sc-202765A sc-202765B | 1 g 5 g 25 g | $67.00 $286.00 $1326.00 | 11 | |
A GABA receptor antagonist, could indirectly affect KCTD4's regulatory role on these receptors. | ||||||
(+)-Bicuculline | 485-49-4 | sc-202498 sc-202498A | 50 mg 250 mg | $82.00 $281.00 | ||
Another GABA receptor antagonist, could influence KCTD4's function in GABAergic signaling. | ||||||
Quinidine | 56-54-2 | sc-212614 | 10 g | $104.00 | 3 | |
Affects potassium channels, potentially influencing KCTD4-related activities. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
Modulates various neurotransmitter systems, might impact KCTD4-related pathways. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
A calcium channel blocker, could indirectly impact pathways involving KCTD | ||||||
5,5-Diphenyl Hydantoin | 57-41-0 | sc-210385 | 5 g | $70.00 | ||
Modulates sodium channels, potentially influencing signaling pathways where KCTD4 is involved. | ||||||
Gabapentin | 60142-96-3 | sc-201481 sc-201481A sc-201481B | 20 mg 100 mg 1 g | $53.00 $94.00 $135.00 | 7 | |
Modulates GABAergic signaling, could indirectly affect KCTD4 function. | ||||||